Discovery the Inhibitors of stomach cancer

• Main Author: 蕭雅霖
• Other Authors: Hsiao, Nai-Wan
• Format: Others
• Language: zh-TW
• Published: 2017
• Online Access: http://ndltd.ncl.edu.tw/handle/7qz345

碩士 === 國立彰化師範大學 === 生物學系 === 105 === Gastric cancer is a gastric mucosal malignant tumor, is a common cancer in the digestive tract, the prevalence of males than women. The cause of gastric cancer is still not fully defined. Recent studies found that gastric cancer should be the impact of the multiple factors ,and diseases that occur in multiple steps. Multiple factors include diet factors, genetic factors, immune factors, Helicobacter pylori and some other risk factors, coupled with a variety of oncogenes during the role, it may lead to the occurrence of gastric cancer. The calcium-sensing receptor (CaSR) plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary calcium excretion. This receptor has a wide range of regulatory functions. Abnormal CaSR function lead to the development of cardiovascular disease and cancer, Differentially expressed in various cancers and normal tissues have been shown to be involved in carcinogenic or tumor suppressive.So CaSR receptors may be one of the targets of future cancer treatment. Cancer cells with a high degree of proliferation and metastasis, and may be resistant to drugs and to avoid the immune system to kill. This study was aimed at establishing CaSR receptor inhibitor drugs platform,and screened out the drug label 18950 for the treatment of gastric cancer ,then a more detailed cell experiments to verify. Confirmed that the results will enter the animal experiments to confirm its efficacy and toxicity of the organism. The results show that tumor growth is inhibited in cell strain experiments and is expected to contribute to the development of new anticancer drugs.